Clinical Trial

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

Name: Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL — clinical trial record (NCT06503263)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-07-10.

Status change: Not Yet Recruiting → Recruiting 2024-09-05

Trial Details

NCT Number	NCT06503263
Lead Sponsor	Navy General Hospital, Beijing
Conditions	Diffuse Large B-cell Lymphoma
Enrollment	240 participants
Start Date	2024-08-30
Primary Completion	2030-07-30 (estimated)
Study Completion	2030-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-09-19